Bristol Myers Squibb and Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl® (luspatercept-aamt) in Adults with Non-Transfusion Dependent(NTD)Beta Thalassemia

close

Get every new post delivered right to your inbox.

Original Source